CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
|Articles|July 15, 2002
- BioPharm International-07-01-2002
- Volume 15
- Issue 7
Virus Inactivation in the 1990's ? and into the 21st Century. Part 1: Skin, Bone, and Cells
Author(s)Gail Sofer
by Gail Sofer, BioReliance Viruses present dangers (and therefore challenges) to biopharmaceutical manufacturing processes. The virus inactivation method chosen depends on the virus and its surrounding medium. This survey article, organized by sample type, lists viral inactivation methods published during the past decade. Part 1 presents data for skin and bone and for cells that are not platelets or blood cells.
Advertisement
Articles in this issue
over 24 years ago
Facilitating Client Audits: The Contract Laboratory Perspectiveover 24 years ago
Knowledge Management: The Four Pillars of Successover 24 years ago
Inside Washington: One Hundred Years of Biotech Regulationover 24 years ago
Guest Editorial: Supreme Court Rules on FestoAdvertisement
Related to this article
AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.
FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
Three case studies show how automated Raman plate reading can triage samples before chromatography in bioprocess development.
This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
Advertisement
Advertisement
Trending on BioPharm International
1
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
2
Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates
3
Samsung Biologics Secures 97.66% of PolyPeptide Shares in Tender Offer
4
Resolving the Speed-Specificity Trade-Off in Biopharma High-Throughput Screening
5